Mankind Pharmaceuticals has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. Under the sub-licensing agreement, Mankind will market the drug under its own trademark while Glenmark will manufacture and supply it to the drug firm. Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society.
In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials. Subsequently, the company launched the drug under the brand names Remo and Remozen.